NCT02076009: Phase 3 - Daratumumab, Lenalidomide & Dex (DRd) VS Len & Dexa (Rd) - MMY3003 (POLLUX)
MMY3003 (POLLUX) Study NCT02076009: Phase 3: A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and...
Dec 19, 2014
394
Myeloma UK - Myeloma Animations Series: High Dose Therapy and Autologous Stem Cell Transplantation
Myeloma UK - Myeloma Animations High Dose Therapy and Autologous Stem Cell Transplantation Learn More: https://www.myeloma.org.uk/
Dec 18, 2014
61
14th International Myeloma Workshop: April 3rd-7th, 2013 Kyoto, Japan
14th International Myeloma Workshop April 3rd-7th, 2013 Kyoto, Japan https://www.myelomasociety.org/publications/ 14th IMW Abstract Book:...
Dec 18, 2014
115
Charlotte Radiology: Port Placement: Dr. Eric Wang
Charlotte Radiology: Port Placement: Dr. Eric Wang
Dec 18, 2014
133
NCT02197221: Phase 3: Bortezomib-Melphalan Conditioning Regimen vs Melphalan - Frontline Transplant
IFM2014-02 NCT02197221: Phase 3: Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With...
Dec 17, 2014
78
NCT02119468: Phase 1/2: Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With RRMM
NCT02119468: Phase 1/2: Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple...
Dec 17, 2014
45
NCT02064387: Phase 1 -Safety Pharm.kinetics Pharm.dynamics Img. & Cl. Activity GSK2857916 - DREAMM-1
DREAMM-1 study Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity...
Dec 16, 2014
226
Myeloma UK - Myeloma Animations Series: Myeloma Kidney Disease
Myeloma UK - Myeloma Animations Myeloma Kidney Disease Learn More: https://www.myeloma.org.uk/
Dec 16, 2014
55
NCT02046070: Phase 2 to Evaluate the Oral Ixazomib (MLN9708) With Cyclophosphamide & Dex Myeloma
NCT02046070: Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients...
Dec 14, 2014
53
NCT02199665: Phase 1: Selinexor, Carfilzomib, & Dexamethasone in Treating Patients With RRMM (SINE)
Multiple Myeloma Research Consortium NCT02199665: Phase 1: Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed...
Dec 13, 2014
112
NCT02181413: Phase 3 - TOURMALINE-MM3 -Oral Ixazomib Citrate (MLN9708) Maintenance in NDMM Post ASCT
TOURMALINE-MM3 A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous...
Dec 13, 2014
371
NCT02045017: Phase 2: Efficacy & Safety of Pom and Dex in RRMM Patients With Renal Insufficiency
NCT02045017: Phase 2: Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency Efficacy and Safety...
Dec 13, 2014
103
NCT02195479 : A Phase 3, Study of Bortezomib, Melphalan, Prednisone & Daratumumab ALCYONE trial
ALCYONE trial NCT02195479: Phase 3: A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared...
Dec 12, 2014
310
Khan Academy: What is a M-Spike? What is the difference b/w asymptomatic MGUS & symptomatic Myeloma
Khan Academy Khan Academy: What is a M-Spike? What is the difference b/w asymptomatic MGUS & symptomatic Myeloma What is a M-Spike? What...
Dec 12, 2014
94
Myeloma UK - Myeloma Animations Series: Myeloma - The Origin of the Myeloma Cell
Myeloma UK - Myeloma Animations Myeloma - The Origin of the Myeloma Cell Learn More: https://www.myeloma.org.uk/
Dec 12, 2014
131
NCT02252172 : Phase 3 - Dara, Lena & Dex VS Len & Dex in previously untreated Myeloma - MAIA STUDY
The MAIA Study NCT02252172: Phase 3: Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in...
Dec 12, 2014
497
NCT02316106: Phase 2 - A Study to Evaluate 3 Dose Schedules of Daratumumab in SMM - CENTAURUS
CENTAURUS A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma The purpose of this study...
Dec 12, 2014
171
NCT02136134: Phase 3 - Daratumumab Plus Bortezomib & Dexa in relapsed Myeloma MMY3004 (CASTOR) Study
The CASTOR Trial Dara Vd DVd NCT02136134: Phase 3: Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants...
Dec 11, 2014
509
NCT02279394: E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in Hi R SMM
NCT02279394: E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma E-PRISM: Phase...
Dec 11, 2014
144